[
  {
    "ts": null,
    "headline": "Integer Appoints Michael Coyle to Board of Directors",
    "summary": "~ New Director Brings Extensive Medical Device Industry Leadership and Technology Experience to Integer Board ~ PLANO, Texas, July 10, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced it has appointed Michael Coyle to its Board of Directors. Coyle brings more than 40 years of leadership in the medical device industry to Integer and joins the Board as a member of the Audi",
    "url": "https://finnhub.io/api/news?id=fa7883a9a585b4cace7f459ad865b1670038f2ead0b04c7303a23b099c11620e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752180720,
      "headline": "Integer Appoints Michael Coyle to Board of Directors",
      "id": 135865806,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "~ New Director Brings Extensive Medical Device Industry Leadership and Technology Experience to Integer Board ~ PLANO, Texas, July 10, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced it has appointed Michael Coyle to its Board of Directors. Coyle brings more than 40 years of leadership in the medical device industry to Integer and joins the Board as a member of the Audi",
      "url": "https://finnhub.io/api/news?id=fa7883a9a585b4cace7f459ad865b1670038f2ead0b04c7303a23b099c11620e"
    }
  },
  {
    "ts": null,
    "headline": "Verve Therapeutics, Inc. (VERV): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this article, we will summarize the bulls’ thesis on VERV. Verve Therapeutics, Inc.’s share was trading at $11.26 as of June 26th. Verve Therapeutics’ stock surged an astounding 75% following Eli Lilly’s $1.3 billion acquisition announcement, signaling a […]",
    "url": "https://finnhub.io/api/news?id=31ea17e8b42987cd5418e7ec79485d8407250f3966672b0c5ad9169ea1c8a7f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752170018,
      "headline": "Verve Therapeutics, Inc. (VERV): A Bull Case Theory",
      "id": 135865807,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this article, we will summarize the bulls’ thesis on VERV. Verve Therapeutics, Inc.’s share was trading at $11.26 as of June 26th. Verve Therapeutics’ stock surged an astounding 75% following Eli Lilly’s $1.3 billion acquisition announcement, signaling a […]",
      "url": "https://finnhub.io/api/news?id=31ea17e8b42987cd5418e7ec79485d8407250f3966672b0c5ad9169ea1c8a7f6"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Comes Out As ADA Winner",
    "summary": "Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will solidify its market dominance for the next 5-7 years. Read more.",
    "url": "https://finnhub.io/api/news?id=b71f4849eb54996b367f6072dd34788ba1aca254fdff35358faab0e56a11a865",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752165108,
      "headline": "Eli Lilly Comes Out As ADA Winner",
      "id": 135862272,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1355656320/image_1355656320.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will solidify its market dominance for the next 5-7 years. Read more.",
      "url": "https://finnhub.io/api/news?id=b71f4849eb54996b367f6072dd34788ba1aca254fdff35358faab0e56a11a865"
    }
  },
  {
    "ts": null,
    "headline": "Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?",
    "summary": "LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.",
    "url": "https://finnhub.io/api/news?id=d05716436a4aed3c0bdf9f48152557b84e6cd1e6bd0f3ed451ebcd3b8fe51691",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752156540,
      "headline": "Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?",
      "id": 135855656,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.",
      "url": "https://finnhub.io/api/news?id=d05716436a4aed3c0bdf9f48152557b84e6cd1e6bd0f3ed451ebcd3b8fe51691"
    }
  },
  {
    "ts": null,
    "headline": "Pharma Companies Remain Calm Amid Fresh Tariff Threat by Trump",
    "summary": "Trump revives tariff threats on pharma imports, but industry giants like LLY and JNJ stay unfazed with major U.S. investments underway.",
    "url": "https://finnhub.io/api/news?id=df287e40eb727c86c9092cf435149978e345a0469131169198519a9fb2846e4e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752154440,
      "headline": "Pharma Companies Remain Calm Amid Fresh Tariff Threat by Trump",
      "id": 135853558,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Trump revives tariff threats on pharma imports, but industry giants like LLY and JNJ stay unfazed with major U.S. investments underway.",
      "url": "https://finnhub.io/api/news?id=df287e40eb727c86c9092cf435149978e345a0469131169198519a9fb2846e4e"
    }
  },
  {
    "ts": null,
    "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
    "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
    "url": "https://finnhub.io/api/news?id=e8b0b8795dba0071d21a2197be5d282be8c6387ef0a512f1ddb03ba82297bd13",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752152402,
      "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
      "id": 135855658,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
      "url": "https://finnhub.io/api/news?id=e8b0b8795dba0071d21a2197be5d282be8c6387ef0a512f1ddb03ba82297bd13"
    }
  },
  {
    "ts": null,
    "headline": "Big Pharma on the Clock as 200% Tariffs Loom",
    "summary": "Drugmakers could get an 18-month window to boost U.S. factories or face massive import levies",
    "url": "https://finnhub.io/api/news?id=add84f741fdae839dce4269c6452a18bd86774cd03714c5eee72151d5eddfe2b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752149824,
      "headline": "Big Pharma on the Clock as 200% Tariffs Loom",
      "id": 135852109,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Drugmakers could get an 18-month window to boost U.S. factories or face massive import levies",
      "url": "https://finnhub.io/api/news?id=add84f741fdae839dce4269c6452a18bd86774cd03714c5eee72151d5eddfe2b"
    }
  }
]